NASDAQ:SCPS Scopus BioPharma Earnings Date & Estimates $0.0004 0.00 (0.00%) As of 11/11/2026 Scopus BioPharma is estimated to report earnings on Wednesday, December 2, 2026. Research:Profile Upcoming Earnings Announcement Announcement DateDecember 2, 2026 Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Scopus BioPharmaScopus BioPharma is expected to post earnings of -$0.22 per share.Consensus EstimatesConsensus EPS-$0.22Prepare for the Earnings CallCompany Profile Scopus BioPharma Earnings FAQ When does Scopus BioPharma report earnings? Scopus BioPharma (NASDAQ:SCPS) is estimated to report earnings on Wednesday, December 2, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What is the consensus EPS estimate for Scopus BioPharma? Analysts expect Scopus BioPharma to post earnings of -$0.22 per share for the quarter. Scopus BioPharma Earnings HeadlinesScopus BioPharma's Subsidiary - Duet BioTherapeutics - Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for ...June 25, 2026 | stockhouse.comScopus Stock Price HistoryJune 10, 2026 | investing.comMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.November 13 at 1:00 AM | Crypto 101 Media (Ad)SCPS Scopus BioPharma Inc.May 31, 2026 | seekingalpha.comScopus Stock Price History - Investing.comJune 29, 2025 | investing.comScopus Biopharma Inc (SCPS) Stock Forums - Investing.comJune 29, 2025 | investing.comSee More Scopus BioPharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Scopus BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scopus BioPharma and other key companies, straight to your email. Email Address About Scopus BioPharmaScopus BioPharma (NASDAQ:SCPS), Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for cancer and inflammatory diseases. The company’s research and development programs are aimed at addressing serious medical conditions with significant unmet treatment needs. Scopus BioPharma’s lead development program has included SCB-313, an investigational antibody-based therapy designed to target Claudin 18.2, a protein expressed on certain cancer cells. The program has been evaluated for potential use in advanced solid tumors, including cancers in which Claudin 18.2 is present. As an investigational product, SCB-313 has not been established as safe or effective for any indication. The company has historically operated as a development-stage biotechnology business serving the pharmaceutical and healthcare markets through research, clinical development and potential commercialization of its proprietary drug candidates. Publicly available information about its broader pipeline, current operations and leadership is limited, so additional details should be confirmed through the company’s regulatory filings and other official disclosures.View Scopus BioPharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense OpportunityThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid? Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
